CoChat
Sign Up
Cited by 489

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Sirtuins: critical regulators at the crossroads between cancer and aging

Saunders, L R, Verdin, E·2007·Oncogene
DOI 10.1038/sj.onc.1210616
Open this paper in CoChat — free account

Abstract

Sirtuins (SIRTs 1-7), or class III histone deacetylases (HDACs), are protein deacetylases/ADP ribosyltransferases that target a wide range of cellular proteins in the nucleus, cytoplasm, and mitochondria for post-translational modification by acetylation (SIRT1, -2, -3 and -5) or ADP ribosylation (SIRT4 and -6). The orthologs of sirtuins in lower organisms play a critical role in regulating lifespan. As cancer is a disease of aging, we discuss the growing implications of the sirtuins in protecting against cancer development. Sirtuins regulate the cellular responses to stress and ensure that damaged DNA is not propagated and that mutations do not accumulate. SIRT1 also promotes replicative senescence under conditions of chronic stress. By participating in the stress response to genomic insults, sirtuins are thought to protect against cancer, but they are also emerging as direct participants in the growth of some cancers. Here, we review the growing implications of sirtuins both in cancer prevention and as specific and novel cancer therapeutic targets.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1210616

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 135

  1. Abdelmohsen K, Pullmann Jr R, Lal A, Kim HH, Galban S, Yang X et al. (2007). Phosphorylation of HuR by Chk2 Regulates SIRT1 Expression. Mol Cell 25: 543–557. · DOI
  2. Aksoy P, Escande C, White TA, Thompson M, Soares S, Benech JC et al. (2006a). Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. Biochem Biophys Res Commun 349: 353–359. · DOI
  3. Aksoy P, White TA, Thompson M, Chini EN . (2006b). Regulation of intracellular levels of NAD: a novel role for CD38. Biochem Biophys Res Commun 345: 1386–1392. · DOI
  4. Ando K, Higami Y, Tsuchiya T, Kanematsu T, Shimokawa I . (2002). Impact of aging and life-long calorie restriction on expression of apoptosis-related genes in male F344 rat liver. Microsc Res Tech 59: 293–300. · DOI
  5. Anisimov VN, Zhukovskaya NV, Loktionov AS, Vasilyeva IA, Kaminskaya EV, Vakhtin YB . (1988). Influence of host age on lung colony forming capacity of injected rat rhabdomyosarcoma cells. Cancer Lett 40: 77–82. · DOI
  6. Ashburner BP, Westerheide SD, Baldwin Jr AS . (2001). The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 21: 7065–7077. · DOI
  7. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD et al. (2006). Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer 95: 1056–1061. · DOI
  8. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR et al. (2007). Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol (in press). · DOI
  9. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD et al. (2001). Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8: 1243–1254. · DOI · Paper page
  10. Bereshchenko OR, Gu W, Dalla-Favera R . (2002). Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 32: 606–613. · DOI
  11. Berrigan D, Perkins SN, Haines DC, Hursting SD . (2002). Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. Carcinogenesis 23: 817–822. · DOI
  12. Bluher M, Kahn BB, Kahn CR . (2003). Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299: 572–574. · DOI · Paper page
  13. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT et al. (2005). Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19: 1751–1759. · DOI
  14. Chen LF, Mu Y, Greene WC . (2002). Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 21: 6539–6548. · DOI · Paper page
  15. Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M et al. (2004). Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 6: 387–398. · DOI
  16. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB . (2005). Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123: 437–448. · DOI
  17. Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M et al. (2003). Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 33: 197–202. · DOI
  18. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P et al. (2003). Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 100: 10794–10799. · DOI · Paper page
  19. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A . (2005). Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 65: 10183–10187. · DOI
  20. Chua KF, Mostoslavsky R, Lombard DB, Pang WW, Saito S, Franco S et al. (2005). Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab 2: 67–76. · DOI
  21. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C et al. (2004a). Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13: 627–638. · DOI
  22. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B et al. (2004b). Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305: 390–392. · DOI · Paper page
  23. Dai JM, Wang ZY, Sun DC, Lin RX, Wang SQ . (2007). SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. J Cell Physiol 210: 161–166. · DOI
  24. Daitoku H, Hatta M, Matsuzaki H, Aratani S, Ohshima T, Miyagishi M et al. (2004). Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci USA 101: 10042–10047. · DOI
  25. Dawid IB, Breen JJ, Toyama R . (1998). LIM domains: multiple roles as adapters and functional modifiers in protein interactions. Trends Genet 14: 156–162. · DOI
  26. De Nigris F, Cerutti J, Morelli C, Califano D, Chiariotti L, Viglietto G et al. (2002). Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer 87: 1479. · DOI
  27. DeGregori J, Johnson DG . (2006). Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 6: 739–748.
  28. Dhordain P, Lin RJ, Quief S, Lantoine D, Kerckaert JP, Evans RM et al. (1998). The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res 26: 4645–4651. · DOI
  29. Dryden SC, Nahhas FA, Nowak JE, Goustin AS, Tainsky MA . (2003). Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol 23: 3173–3185. · DOI
  30. Feng L, Lin T, Uranishi H, Gu W, Xu Y . (2005). Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 25: 5389–5395. · DOI · Paper page
  31. Finkel T, Holbrook NJ . (2000). Oxidants, oxidative stress and the biology of ageing. Nature 408: 239–247. · DOI · Paper page
  32. Ford J, Jiang M, Milner J . (2005). Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65: 10457–10463. · DOI
  33. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al. (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391–400. · DOI
  34. Frye R . (2002). ‘SIRT8’ expressed in thyroid cancer is actually SIRT7. Br J Cancer 87: 1479. · DOI
  35. Frye RA . (1999). Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 260: 273–279. · DOI
  36. Fu M, Liu M, Sauve AA, Jiao X, Zhang X, Wu X et al. (2006). Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol 26: 8122–8135. · DOI
  37. Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D et al. (2003). Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23: 8563–8575. · DOI
  38. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L et al. (2000). p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275: 20853–20860. · DOI
  39. Fukuoka M, Daitoku H, Hatta M, Matsuzaki H, Umemura S, Fukamizu A . (2003). Negative regulation of forkhead transcription factor AFX (Foxo4) by CBP-induced acetylation. Int J Mol Med 12: 503–508.
  40. Fulco M, Schiltz RL, Iezzi S, King MT, Zhao P, Kashiwaya Y et al. (2003). Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol Cell 12: 51–62. · DOI
  41. Fulda S, Debatin KM . (2006). Resveratrol modulation of signal transduction in apoptosis and cell survival: a mini-review. Cancer Detect Prev 30: 217–223. · DOI
  42. Furukawa-Hibi Y, Kobayashi Y, Chen C, Motoyama N . (2005). FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal 7: 752–760. · DOI
  43. Gil J, Bernard D, Peters G . (2005). Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol 24: 117–125. · DOI
  44. Glatt SJ, Chayavichitsilp P, Depp C, Schork NJ, Jeste DV . (2007). Successful aging: from phenotype to genotype. Biol Psychiatry (in press). · DOI
  45. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ et al. (2006). SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 126: 941–954. · DOI · Paper page
  46. Hallows WC, Lee S, Denu JM . (2006). Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci USA 103: 10230–10235. · DOI · Paper page
  47. Han X, Berardi P, Riabowol K . (2006). Chromatin modification and senescence: linkage by tumor suppressors? Rejuvenation Res 9: 69–76. · DOI
  48. Hanahan D, Weinberg RA . (2000). The hallmarks of cancer. Cell 100: 57–70. · DOI · Paper page
  49. Hassa PO, Haenni SS, Elser M, Hottiger MO . (2006). Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev 70: 789–829. · DOI
  50. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S et al. (2006). Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66: 4368–4377. · DOI
  51. Hida Y, Kubo Y, Murao K, Arase S . (2006). Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res 239: 103–106.
  52. Higami Y, Shimokawa I, Tomita M, Okimoto T, Koji T, Kobayashi N et al. (1997). Aging accelerates but life-long dietary restriction suppresses apoptosis-related Fas expression on hepatocytes. Am J Pathol 151: 659–663.
  53. Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H et al. (2003). Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 309: 558–566. · DOI
  54. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T et al. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22: 3551–3555.
  55. Holmes-McNary M, Baldwin Jr AS . (2000). Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 60: 3477–3483.
  56. Huffman DM, Johnson MS, Watts A, Elgavish A, Eltoum IA, Nagy TR . (2007). Cancer progression in the transgenic adenocarcinoma of mouse prostate mouse is related to energy balance, body mass, and body composition, but not food intake. Cancer Res 67: 417–424. · DOI
  57. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC . (2003). Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 54: 131–152. · DOI
  58. Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S et al. (2006). SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 26: 945–947. · DOI
  59. Itahana K, Dimri G, Campisi J . (2001). Regulation of cellular senescence by p53. Eur J Biochem 268: 2784–2791. · DOI · Paper page
  60. Iyer NG, Ozdag H, Caldas C . (2004). p300/CBP and cancer. Oncogene 23: 4225–4231. · DOI
  61. Jackson MD, Schmidt MT, Oppenheimer NJ, Denu JM . (2003). Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem 278: 50985–50998. · DOI
  62. Jeppesen P, Turner BM . (1993). The inactive X chromosome in female mammals is distinguished by a lack of histone H4 acetylation, a cytogenetic marker for gene expression. Cell 74: 281–289. · DOI
  63. Jones JM, Attardi L, Godley LA, Laucirica R, Medina D, Jacks T et al. (1997). Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ 8: 829–838.
  64. Jones PA, Baylin SB . (2007). The epigenomics of cancer. Cell 128: 683–692. · DOI · Paper page
  65. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R et al. (2006). Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 66: 11341–11347. · DOI
  66. Kalkhoven E, Teunissen H, Houweling A, Verrijzer CP, Zantema A . (2002). The PHD type zinc finger is an integral part of the CBP acetyltransferase domain. Mol Cell Biol 22: 1961–1970. · DOI
  67. Kamel C, Abrol M, Jardine K, He X, McBurney MW . (2006). SirT1 fails to affect p53-mediated biological functions. Aging Cell 5: 81–88. · DOI
  68. Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, Sardet C et al. (2003). Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278: 2758–2766. · DOI
  69. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J et al. (2006). Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23: 607–618. · DOI · Paper page
  70. Kobayashi Y, Furukawa-Hibi Y, Chen C, Horio Y, Isobe K, Ikeda K et al. (2005). SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med 16: 237–243.
  71. Krummel KA, Lee CJ, Toledo F, Wahl GM . (2005). The C terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci USA 102: 10188–10193. · DOI · Paper page
  72. Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, Kirmizis A et al. (2005). Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA 102: 1859–1864. · DOI
  73. Labalette C, Renard CA, Neuveut C, Buendia MA, Wei Y . (2004). Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin. Mol Cell Biol 24: 10689–10702. · DOI
  74. Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L et al. (2000). The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci USA 97: 5807–5811. · DOI · Paper page
  75. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S et al. (2002). Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21: 2383–2396. · DOI
  76. Lennox RW, Cohen LH . (1983). The histone H1 complements of dividing and nondividing cells of the mouse. J Biol Chem 258: 262–268. · DOI
  77. Li F, Chong ZZ, Maiese K . (2006). Cell Life versus cell longevity: the mysteries surrounding the NAD+ precursor nicotinamide. Curr Med Chem 13: 883–895. · DOI
  78. Lim CS, Potts M, Helm RF . (2006). Nicotinamide extends the replicative life span of primary human cells. Mech Ageing Dev 127: 511–514. · DOI
  79. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al. (2006). Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67. · DOI
  80. Longo VD, Kennedy BK . (2006). Sirtuins in aging and age-related disease. Cell 126: 257–268. · DOI · Paper page
  81. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A et al. (2001). Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137–148. · DOI · Paper page
  82. Mai V, Colbert LH, Berrigan D, Perkins SN, Pfeiffer R, Lavigne JA et al. (2003). Calorie restriction and diet composition modulate spontaneous intestinal tumorigenesis in Apc(Min) mice through different mechanisms. Cancer Res 63: 1752–1755.
  83. Manna SK, Mukhopadhyay A, Aggarwal BB . (2000). Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164: 6509–6519. · DOI
  84. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T . (2000). Regulation of E2F1 activity by acetylation. EMBO J 19: 662–671. · DOI
  85. McLure KG, Takagi M, Kastan MB . (2004). NAD+ modulates p53 DNA binding specificity and function. Mol Cell Biol 24: 9958–9967. · DOI
  86. Mendoza-Alvarez H, Alvarez-Gonzalez R . (2001). Regulation of p53 sequence-specific DNA-binding by covalent poly(ADP-ribosyl)ation. J Biol Chem 276: 36425–36430. · DOI
  87. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I . (2005). Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16: 4623–4635. · DOI · Paper page
  88. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L et al. (2006). Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124: 315–329. · DOI · Paper page
  89. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W et al. (2004). Mammalian SIRT1 represses forkhead transcription factors. Cell 116: 551–563. · DOI
  90. Muller JM, Metzger E, Greschik H, Bosserhoff AK, Mercep L, Buettner R et al. (2002). The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. EMBO J 21: 736–748. · DOI
  91. Nemoto S, Fergusson MM, Finkel T . (2004). Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306: 2105–2108. · DOI
  92. Niu H . (2002). The protooncogene BCL-6 in normal and malignant B cell development. Hematol Oncol 20: 155–166. · DOI
  93. Niu H, Ye BH, Dalla-Favera R . (1998). Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev 12: 1953–1961. · DOI
  94. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E . (2003). The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11: 437–444. · DOI
  95. North BJ, Verdin E . (2004). Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol 5: 224. · DOI
  96. Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP . (2002). SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci USA 99: 13653–13658. · DOI
  97. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M et al. (2006). Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25: 176–185. · DOI
  98. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S et al. (2000). PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207–210. · DOI
  99. Piva R, Belardo G, Santoro MG . (2006). NF-kappaB: a stress-regulated switch for cell survival. Antioxid Redox Signal 8: 478–486. · DOI
  100. Poirier GG, Savard P . (1980). ADP-ribosylation of pancreatic histone H1 and of other histones. Can J Biochem 58: 509–515. · DOI
  101. Porcu M, Chiarugi A . (2005). The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci 26: 94–103. · DOI
  102. Reya T, Morrison SJ, Clarke MF, Weissman IL . (2001). Stem cells, cancer, and cancer stem cells. Nature 414: 105–111. · DOI · Paper page
  103. Roth GS, Ingram DK, Lane MA . (2001). Caloric restriction in primates and relevance to humans. Ann N Y Acad Sci 928: 305–315. · DOI
  104. Rowinsky EK, Calvo E . (2006). Novel agents that target tubulin and related elements. Semin Oncol 33: 421–435. · DOI
  105. Sawada M, Sun W, Hayes P, Leskov K, Boothman DA, Matsuyama S . (2003). Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 5: 320–329. · DOI
  106. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G . (2007). Genome regulation by polycomb and trithorax proteins. Cell 128: 735–745. · DOI
  107. Schwer B, Bunkenborg J, Verdin RO, Andersen JS, Verdin E . (2006). Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci USA 103: 10224–10229. · DOI · Paper page
  108. Schwer B, North BJ, Frye RA, Ott M, Verdin E . (2002). The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol 158: 647–657. · DOI
  109. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M et al. (2005). Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262–1266. · DOI
  110. Shand RL, Gelmann EP . (2006). Molecular biology of prostate-cancer pathogenesis. Curr Opin Urol 16: 123–131. · DOI
  111. Simbulan-Rosenthal CM, Rosenthal DS, Luo RB, Samara R, Jung M, Dritschilo A et al. (2001). Poly(ADP-ribosyl)ation of p53 in vitro and in vivo modulates binding to its DNA consensus sequence. Neoplasia 3: 179–188. · DOI
  112. Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT . (2006). Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer 13: 653–666. · DOI
  113. Smith JS, Brachmann CB, Celic I, Kenna MA, Muhammad S, Starai VJ et al. (2000). A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci USA 97: 6658–6663. · DOI · Paper page
  114. Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, DiStefano PS et al. (2006). Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 26: 28–38. · DOI
  115. Sommer M, Poliak N, Upadhyay S, Ratovitski E, Nelkin BD, Donehower LA et al. (2006). DeltaNp63alpha overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse. Cell Cycle 5: 2005–2011. · DOI
  116. Stankovic-Valentin N, Deltour S, Seeler J, Pinte S, Vergoten G, Guerardel C et al. (2007). An Acetylation/Deacetylation-SUMOylation switch through a phylogenetically conserved {psi}KxEP motif in the tumor suppressor HIC1 (Hypermethylated in Cancer 1) regulates transcriptional repression activity. Mol Cell Biol 27: 2661–2675. · DOI
  117. Strickler HD, Wylie-Rosett J, Rohan T, Hoover DR, Smoller S, Burk RD et al. (2001). The relation of type 2 diabetes and cancer. Diabetes Technol Ther 3: 263–274. · DOI
  118. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y . (2006). Nucleo-cytoplasmic shuttling of NAD+-dependent histone deacetylase SIRT1. J Biol Chem 282: 6823–6832. · DOI
  119. Thompson PR, Wang D, Wang L, Fulco M, Pediconi N, Zhang D et al. (2004). Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol 11: 308–315. · DOI · Paper page
  120. Vainio H, Kaaks R, Bianchini F . (2002). Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev 11 (Suppl 2): S94–S100.
  121. van der Heide LP, Smidt MP . (2005). Regulation of FoxO activity by CBP/p300-mediated acetylation. Trends Biochem Sci 30: 81–86. · DOI
  122. van der Horst A, Tertoolen LG, de Vries-Smits LM, Frye RA, Medema RH, Burgering BM . (2004). FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem 279: 28873–28879. · DOI
  123. van der Veer E, Ho C, O'Neil C, Barbosa N, Scott R, Cregan SP et al. (2007). Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem 282: 10841–10845. · DOI
  124. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D . (2004). Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 16: 93–105. · DOI · Paper page
  125. Vaquero A, Scher MB, Lee DH, Sutton A, Cheng HL, Alt FW et al. (2006). SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev 20: 1256–1261. · DOI
  126. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al. (2001). hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149–159. · DOI
  127. Vousden KH, Lu X . (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594–604. · DOI
  128. Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y et al. (2006). Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 8: 1025–1031. · DOI
  129. Wang W, Yang X, Cristofalo VJ, Holbrook NJ, Gorospe M . (2001). Loss of HuR is linked to reduced expression of proliferative genes during replicative senescence. Mol Cell Biol 21: 5889–5898. · DOI
  130. Waterbor JW, Bueschen AJ . (1995). Prostate cancer screening (United States). Cancer Causes Control 6: 267–274. · DOI
  131. Yamamoto H, Okamoto H . (1980). Protection by picolinamide, a novel inhibitor of poly (ADP-ribose) synthetase, against both streptozotocin-induced depression of proinsulin synthesis and reduction of NAD content in pancreatic islets. Biochem Biophys Res Commun 95: 474–481. · DOI
  132. Yang T, Sauve A . (2006). NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. Aaps J 8: E632–E643. · DOI
  133. Yang Y, Hou H, Haller EM, Nicosia SV, Bai W . (2005). Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J 24: 1021–1032. · DOI
  134. Zhang J . (2003). Are poly(ADP-ribosyl)ation by PARP-1 and deacetylation by Sir2 linked? Bioessays 25: 808–814. · DOI
  135. Zhong H, May MJ, Jimi E, Ghosh S . (2002). The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9: 625–636. · DOI

Cited by

Sorted by citations

Metadata

Authors
Saunders, L. R., & Verdin, E.
Venue
Oncogene
Publisher
Springer Science and Business Media LLC
Published
2007-08-13
Volume
26
Issue
37
Pages
5489-5504
ISSN
  • 0950-9232
  • 1476-5594
DOI
10.1038/sj.onc.1210616
Cited by
489
References
17
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review